Clinical Trials
50 trialsNCT03404193 2026-03-10
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03926624 2026-01-22
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 3 Terminated
NCT05799079 2026-01-09
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT05918055 2025-12-02
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT05148234 2025-09-30
BMS-986253 in Myelodysplastic Syndromes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT06941688 2025-04-24
Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma
Seoul National University Hospital
Phase 2 Terminated
NCT05360264 2025-03-24
ORIENTATE
Regina Elena Cancer Institute
Phase 2 Terminated
NCT05524857 2024-04-23
Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
Columbia University
Phase 1 Terminated
NCT04113616 2024-03-22
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Kartos Therapeutics, Inc.
Phase 1/2 Terminated
NCT02608268 2023-12-06
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Novartis
Phase 1/2 Terminated
NCT03593915 2023-11-09
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT03233724 2023-05-31
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02203773 2023-05-16
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
AbbVie
Phase 1 Terminated
NCT01882660 2022-12-19
DECO
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase NA Terminated
NCT03063203 2022-06-02
Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Washington University School of Medicine
Phase 2 Terminated
NCT03295552 2022-04-06
DETECT
Shanghai Jiao Tong University School of Medicine
Phase 2 Terminated
NCT04051996 2021-10-15
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
Yale University
Phase 2 Terminated
NCT04252248 2021-10-06
DERANO
University Hospital Heidelberg
Phase 1 Terminated
NCT03113071 2021-03-16
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT01483690 2020-10-27
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Terminated
NCT01498445 2020-10-22
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02010645 2020-01-02
Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02954653 2019-11-21
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
Pfizer
Phase 1 Terminated
NCT02343939 2019-11-15
ENTO in AML
Gilead Sciences
Phase 1/2 Terminated
NCT03395873 2019-08-21
Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy
Milton S. Hershey Medical Center
Phase 1 Terminated
NCT03146871 2019-04-18
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent
University of Southern California
Phase 2 Terminated
NCT02412475 2019-01-24
Epigenetic Reprogramming in Relapse AML
Medical College of Wisconsin
Phase 1 Terminated
NCT02785900 2018-12-12
CASCADE
Seagen Inc.
Phase 3 Terminated
NCT00791271 2018-11-09
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02469415 2018-10-16
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01846624 2018-09-27
Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Stanford University
Phase 2 Terminated
NCT01876641 2018-09-19
ML28604
University of Iowa
Phase 1 Terminated
NCT02532010 2018-06-15
Pacritinib
Weill Medical College of Cornell University
Phase 2 Terminated
NCT02332889 2018-05-04
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
University of Louisville
Phase 1/2 Terminated
NCT02141477 2018-02-13
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00882206 2017-12-28
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00925132 2017-07-02
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
University of Iowa
Phase 1/2 Terminated
NCT01607645 2017-03-31
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT02234037 2017-01-30
Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60
Emory University
Phase 1 Terminated
NCT02029417 2016-05-09
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00630994 2015-12-30
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
Mayo Clinic
Phase 2 Terminated
NCT01194908 2015-01-26
Re-expression of ER in Triple Negative Breast Cancers
Emory University
Phase 1/2 Terminated
NCT00701298 2014-02-24
Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00049582 2013-09-30
Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00748527 2013-07-10
Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00042796 2013-01-23
Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00089089 2013-01-07
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00113321 2012-08-07
Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00561912 2011-12-26
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00886457 2011-07-20
5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates
Nevada Cancer Institute
Phase 1 Terminated